Disseminated plasmablastic lymphoma

Sharma, Rohit; Abdou, Sherif; Plymyer, Matthew R.; Rohatgi, Chand

doi:10.1016/j.jamcollsurg.2004.03.028

Cited by 7 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A good response to HAART was reported in 10 cases; in which nine patients were reported to be alive at the time of publication. Only one patient was reported to have no response to HAART, and he died of an overwhelming infection 1 month after PBL diagnosis [21].…”

Section: Resultsmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a distinct subtype of non-Hodgkin B-cell lymphoma, originally described with a strong predilection to the oral cavity of human immunodeficiency virus (HIV)-infected individuals. Data regarding patient age and gender, HIV status, initiation of and response to highly active antiretroviral therapy (HAART), tumor extent, pathology, treatment, and outcome were extracted from 112 cases of PBL identified in the literature. The median age at presentation was 38 years with a male predominance of 7:1, and the median CD41 count was 178 cells/mm 3 . PBL presented on average 5 years after diagnosis of HIV. Common primary sites of presentation included the oral cavity, gastrointestinal tract, and lymph nodes. Most cases presented with either stage I or stage IV disease. There was a variable expression of B-cell markers in tumor cells, but plasma cell markers were expressed in all cases. EBV was detected in 74%. Chemotherapy was used to treat 55% patients and was combined with radiotherapy in 21% cases. Complete response was obtained in 66% of treated cases; the majority of these responses were seen after CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). The refractory/relapsed disease rate was 54%. Death occurred in 53% of patients, with a median overall survival of 15 months. Sex, CD41 count, viral load, clinical stage, EBV status, primary site of involvement, and use of CHOP failed to show an association with survival. PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men. Am. J. Hematol. 83:804-809, 2008. V

show abstract

Section: Resultsmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

show abstract

“…Previous of PBL in HIV-positive individuals have found comparable results. 7,[38][39][40] In contrast, the mean age for oral PBL development in HIV-negative patients is 54.1 years. 41 Among the cases, two of them were reported in paediatric patients, and both presented an aggressive course.…”

Section: Discussionmentioning

confidence: 98%

“…Extraoral involvement was reported in 26.6% of the 59 manuscripts that presented this information. The main extraoral sites were bone marrow 1,7,11,33,39 and central nervous system. 1,39 The cases without extraoral involvement had, on average, longer survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oral plasmablastic lymphoma in a HIV‐positive woman: Literature review and case report

et al. 2021

View full text Add to dashboard Cite

We provide a comprehensive review of plasmablastic lymphoma (PBL) in HIV-positive patients and report a case of HIV-associated oral plasmablastic lymphoma. We complied and discussed demographic, clinical, histopathological, immunohistochemical, therapeutic and prognostic features of 105 cases reported in English and Spanish literature.The inclusion criteria were documented cases of confirmed PBL of the oral cavity in HIV-positive patients. Only cases with definitive microscopic diagnosis of PBL and description of HIV infection were included. Reports with insufficient clinical information of the patients were excluded. The literature review revealed 105 cases of HIV-associated oral PBL in 46 published manuscripts. In addition, we reported the case of an aggressive oral PLB arising in a 30-year-old HIV-positive female. This study provides a comprehensive review of clinical and microscopical landscape of PBL. Additionally, our data suggest that case reports should be more rigorous and detailed about the clinical findings, in order to facilitate the understanding of the clinical presentation pattern of oral PBL.

show abstract

“…PBLs can be disseminated [31] and can display extensive bony metastases by CT and positron emission tomography (PET) scans [3,32], but they commonly show negative initial bone marrow biopsies. Widely disseminated bony disease in PBL patients was previously unrecognized and can lead to major confusion with multiple myeloma (Fig.…”

Section: Extramedullary Plasmablastic Tumors Secondary To Plasma Cellmentioning

confidence: 99%

Diffuse large B-cell lymphomas with plasmablastic differentiation

Teruya‐Feldstein

2005

Curr Oncol Rep

View full text Add to dashboard Cite

Recent evidence suggests that diffuse large B-cell lymphoma (DLBCL) with plasmablastic differentiation represents a clinically heterogeneous spectrum with different clinicopathologic characteristics representing distinct entities. Subtypes of DLBCL with plasmablastic features and terminal B-cell differentiation include plasmablastic lymphoma (PBL) of oral mucosa type; PBL with plasmacytic differentiation; primary effusion lymphoma (PEL); KSHV-positive solid lymphoma/extracavitary PEL/HHV-8 associated DLBCL; and DLBCL expressing ALK. In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation but maintain a mature B-cell (CD20 positive) phenotype. These tumors as well as extramedullary plasmablastic tumors secondary to multiple myeloma or plasmacytomas are included in the differential diagnosis. In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis.

show abstract

Disseminated plasmablastic lymphoma

Cited by 7 publications

References 5 publications

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

Oral plasmablastic lymphoma in a HIV‐positive woman: Literature review and case report

Diffuse large B-cell lymphomas with plasmablastic differentiation

Contact Info

Product

Resources

About